A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Conditions

• Ulcerative Colitis
• Ulcerative Colitis Chronic

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Eltrekibart — DRUG
  Administered
• Mirikizumab — DRUG
  Administered
• Placebo — DRUG
  Administered

Study Details

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

Key Dates

Start date

Oct 10, 2024

Status verified

Apr 2026

Primary completion

Dec 31, 2027

Completion

Sep 30, 2028

Study Design

Enrollment

140 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Eltrekibart + Placebo
  Participants will receive eltrekibart with placebo, eltrekibart or mirikizumab.
• Experimental: Mirikizumab + Placebo
  Participants will receive mirikizumab and placebo or mirikizumab.
• Experimental: Eltrekibart + Mirikizumab
  Participants will receive eltrekibart and mirikizumab in combination or separately as monotherapy.
• Experimental: Placebo
  Participants will receive placebo or mirikizumab.

Primary Outcome Measure

Percentage of Participants Achieving Clinical Remission [ Time Frame: Week 12 ]

Central Contacts

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  1-317-615-4559
  [email protected]
• Physicians interested in becoming principal investigators please contact
  [email protected]

Locations (46)

Find similar trials in Chandler, AZ

Related Studies

• Improving the Quality of Care for Adults With Inflammatory Bowel Disease
  Enrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
• The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
  Recruiting · Stanford University · Palo Alto, California
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
• Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
  PHASE1/PHASE2 · Recruiting · Children's Hospital Medical Center, Cincinnati · Hartford, Connecticut